Abstract 1333: Bigelovin Inhibits Colorectal Cancer by Suppressing the Growth and Inducing Apoptosis Both in Vitro and in Vivo
Ming-Yue Li,Grace Gar-Lee Yue,Stephen Kwok-Wing Tsui,Kwok-Pui Fung,Ning-Hua Tan,Clara Bik-San Lau
DOI: https://doi.org/10.1158/1538-7445.am2016-1333
IF: 11.2
2016-01-01
Cancer Research
Abstract:Colorectal cancer (CRC) is one of the most common cancers with high incidence and mortality worldwide. In 2014, CRC was the second commonest cancer and second leading cause of cancer deaths in Hong Kong. National Cancer Institute estimates that 132,700 people will be diagnosed with CRC and 49,700 people will die from the disease in 2015 worldwide. Despite effectiveness of the chemotherapeutics, severe side effects often affect patients’ normal life. Traditional Chinese medicines can be a good source of anti-tumor agent with better safety profile. Here, we reported a sesquiterpene lactone (bigelovin) isolated from Inula helianthus- aquatica, which was shown to induce anti-angiogenesis1 and apoptosis2 in vitro. Although previous studies reported its apoptotic effects on various cell lines, there were no detailed mechanistic or animal studies on its effect on colon cancer cells. To further explore its effect on CRC, we used both in vitro and in vivo assays. The effects of bigelovin in vitro were determined by Annexin V/PI double staining, cell cycle assay and western blotting. Bigelovin was shown to have better selectivity in colon cancer cells than primary normal colon cells. Besides, CRC cells treated with bigelovin resulted in decrease in cell proliferation and increase in apoptosis in both time- and dose-dependent manner. Western blot results also showed caspase activation and protein changes of key molecules (p-H2A.X-DNA damage marker, Cyclin B1-cell cycle, etc). Furthermore, bigelovin (20 mg/kg) significantly reduced the growth of CRC cells-driven tumors in vivo without severe side effects comparing to FOLFOX (containing folinic acid, 5-fluorouracil and oxaliplatin) treatment. Taken together, these results suggested that bigelovin can be a promising therapeutic candidate for colorectal cancer. References: 1. Yue, G.G.L., et al. Anti-angiogenesis and immunomodulatory activities of an anti-tumor sesquiterpene bigelovin isolated from Inula helianthus-aquatica. Eur J Med Chem, 2013, 59: 243-52. 2. Zhang, H.H., et al. Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells. Acta Pharmacol Sin, 2015, 36(4): 507-16. Citation Format: Ming-Yue Li, Grace Gar-Lee Yue, Stephen Kwok-Wing Tsui, Kwok-Pui Fung, Ning-Hua Tan, Clara Bik-San Lau. Bigelovin inhibits colorectal cancer by suppressing the growth and inducing apoptosis both in vitro and in vivo. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1333.